Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 12/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CCNH | P51946 | 1/20 | 0.37 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.37 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312155 | 0.91 | IGF1R (0.43) | IGF1RNTRK1 | |
| SCHEMBL16556861 | 0.91 | IGF1R (0.42) | IGF1RNTRK1PLK4 | |
| SCHEMBL10312188 | 0.89 | JAK2 (0.41) | NTRK1PLK4CDK7NTRK3NTRK2 | |
| SCHEMBL10312200 | 0.88 | GRK6 (0.35) | IGF1RNTRK1PLK4CDK7NTRK3 | |
| SCHEMBL10312084 | 0.86 | NTRK1 (0.46) | IGF1RNTRK1PLK4 | |
| SCHEMBL10312157 | 0.81 | IGF1R (0.47) | IGF1RPLK4 | |
| SCHEMBL16556865 | 0.81 | IGF1R (0.41) | IGF1RNTRK1 | |
| SCHEMBL10312193 | 0.80 | AURKA (0.41) | IGF1RNTRK1PLK4CDK7NTRK3 | |
| SCHEMBL10312072 | 0.80 | IDH2 (0.41) | IGF1RNTRK1PLK4CDK7NTRK3 | |
| SCHEMBL10312134 | 0.79 | KMT2A (0.37) | IGF1RNTRK1PLK4CDK7NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | IGF1R 1148/4885NTRK1 482/4885PLK4 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.